~ Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced changes to its executive leadership team in order to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure.

John Trizzino has been appointed as President and Chief Operating Officer for the Company. In this role, Mr. Trizzino will lead the commercial; chemistry, manufacturing and controls or CMC; and regulatory functions. He will also serve on the Company's executive leadership team.

John Herrmann, current Chief Legal Officer and Corporate Secretary, will retire effective December 8th, with Mark Casey joining the Company as his successor effective December 11th. Mr. Casey will also serve on the Company's executive leadership team.

John C. Jacobs, President and Chief Executive Officer of Novavax stated that "we are keenly focused on effectively delivering our COVID-19 product to market and evolving Novavax's scale and structure to position the Company for future success". He further added that "In his new role as Chief Operating Officer, John Trizzino will focus on all aspects of successful product delivery, both for the 2023-2024 vaccination season and beyond".

More on Marylandian

• Sip Social Co. Partners With Omnify To Streamline User Experience Across Growing Operations
• Fred Nassiri Relaunches "Love Sees No Colour"
• Vibrint Enhances Executive Team with National Security Leader Jim Robb as Chief Strategy Officer
• Maryland Department of Agriculture Seeks Exhibitors for 2024 Seafood Expo North America
• The Samuel Lawrence Foundation Presents Live from Dubai: First Friday Series Webinar on Dec 1

Mr. Trizzino has over 25 years of experience in the vaccines market with 12 years at Novavax where he served as Executive Vice President, Chief Commercial Officer and Chief Business Officer among other roles such as Chief Financial Officer, Senior Vice President of Commercial Operations and Senior Vice President of Business Development. Prior to Novavax he served as Chief Executive Officer of Immunovaccine where he successfully led the company into clinical development within infectious disease and cancer immunotherapy business along with holding leadership roles at MedImmune LLC (now AstraZeneca), ID Biomedical and Henry Schein Incorporated. He holds a Bachelor of Science from Long Island University along with a Master of Business Administration from New York University Stern School of Business.

Mr. Casey brings more than 30 years of experience in life sciences sector having served most recently as Chief Legal Officer & Corporate Secretary at Bryn Pharma along with being Chief Legal Officer & Corporate Secretary at Mallinckrodt Pharmaceuticals where he led business turnaround inclusive of enhancing profitability through rationalization of R&D portfolio among other initiatives such as identifying applications for underutilized manufacturing capacity & executive level changes earlier in his career at Idera Pharmaceuticals & Hologic along with roles at Boston Scientific & EMC Corp., holding a Bachelor of Science from Syracuse University & Juris Doctor from Suffolk University Law School respectively .

More on Marylandian

• Wohler makes the Evertz Quartz Protocol available for their iAM-SUM audio monitors & iVAM-SUM AV monitors
• Genuine Hospitality, LLC Adds Two, Southwest Florida Hotels, to Growing Portfolio
• The CPSE Shenzhen 2023 was inaugurated on October
• Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
• Baltimore Fashion Week Presents Style Talks 2024: Unveiling the Future of Fashion

Novavax is focused on improving health by discovering, developing & commercializing innovative vaccines to help protect against serious infectious diseases while currently evaluating vaccines for COVID-19, influenza & COVID-19 & influenza combined based out Gaithersburg Maryland U.S.. For more information please visit novavax .com & LinkedIn .

---

Show All News | Report Violation